Portfolio | Avedro融资2500万美元，礼来亚洲基金领投

2018年5月2日，位于美国马萨诸塞州的Waltham市的Avedro公司宣布成功融资2500万美元。Avedro是一家专注眼科的制药和医疗器械公司，也是角膜重塑领域的全球领导者。这次2500万美元融资由礼来亚洲基金（LAV）领投。现有投资者OrbiMed Advisors，InterWest Partners和HealthQuest Capital跟投。Avedro将利用这笔资金进行产品开发，临床研究和商业活动，包括扩大销售和争取医保支持。

Avedro公司首席执行官Reza Zadno博士说：“Avedro的使命是开发无创角膜重塑治疗方法，以保护和改善视力，并提高患者的生活质量。这轮新融资汇集了致力于帮助我们实现这一目标的杰出投资者集团。这将使我们能够加速推广FDA批准的唯一交联治疗方法，并加速开发我们的下一代角膜重塑应用技术。”

Zadno博士补充说：“我们对与礼来亚洲基金的新合作关系感到特别兴奋。礼来亚洲基金在制药行业和亚洲市场方面的丰富经验，将对扩大我们的产品组合和全球影响力具有无可估量的价值。”

伴随此轮融资，礼来亚洲基金的合伙人卢红波博士作为LAV的代表已加入Avedro董事会。礼来亚洲基金于2008年成立时是礼来公司在亚洲的风险投资公司，但现在是一家独立的全球医疗投资公司，专注于生命科学和医疗保健领域从初创到商业化的各个阶段的投资机会。卢博士在加入LAV前是OrbiMed Advisors在亚洲地区的董事总经理。

卢博士说，“Avedro在推广角膜重塑产品方面的进展，以及其产品在美国市场的扩张速度都给我留下了深刻印象。我很荣幸有机会与这样一个由经验丰富的行业资深人士和投资人组成的团队合作。我们将帮助Avedro进一步推进其临床项目，并发现新的无创性治疗方法，以改善全球患者的视力。”

关于礼来亚洲基金（LAV）

礼来亚洲基金（LAV）成立于2008年，总部设在上海，并在北加州和香港设有办事处。 LAV是一家生命科学和医疗保健行业投资公司，主要专注于生物制药，医疗技术和诊断产品。作为领先的生命科学投资基金，LAV向其投资组合公司提供资本，行业专长和全球资源，以加速其发展。

关于Avedro公司

Avedro是一家私人控股的制药和医疗设备公司，也是角膜重塑领域的全球领导者。我们的专利交联技术由药物制剂和医疗器械组成，已被批准在全球许多国家销售。我们继续开发具有知识产权的角膜重塑产品，用于治疗圆锥角膜和角膜扩张。产品还可用于屈光矫正，来替代隐形眼镜和眼镜。圆锥角膜和角膜扩张是罕见眼睛疾病，会严重威胁视力和视觉。角膜逐渐变薄并变弱，导致锥体突出和引起角膜的光学不规则性。其继续发展将显著损害视力。

在Avedro，我们的使命是为世界各地的眼科护理专业人员生产和提供创新性的角膜重塑微创药物和设备，从而改善患者的视力和生活质量。

附英文新闻： 

Avedro Announces $25 Million in Funding to Fuel Innovation and Commercial Growth

Hongbo Lu, PhD, Joins Avedro Board of Directors

Waltham, Massachusetts, USA, May 02, 2018

Avedro,Inc., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that it has secured $25 million in financing led by Lilly Asia Ventures (LAV) with major participation from existing investors OrbiMed Advisors, InterWest Partners and HealthQuest Capital. Avedro will leverage this funding to invest in product development, clinical studies and commercial efforts, including expansion of sales and reimbursement support.

“Avedro’s mission is to develop non-invasive corneal remodeling treatments that protect and improve vision and dramatically better patients’ lives,” said Reza Zadno, PhD, CEO of Avedro. “This new funding brings together an exceptional syndicate of investors who are committed to helping us achieve this goal. It will allow us to accelerate adoption of the only FDA-approved cross-linking treatment and the development of our next-generation corneal remodeling applications.”

Dr. Zadno added, “We are particularly excited about our new partnership with Lilly Asia Ventures whose expertise in the pharmaceuticals industry and in Asian markets will be invaluable as we expand our product portfolio and global reach.”

In connection with this financing, Hongbo Lu, PhD, has joined the Avedro Board of Directors as a representative of LAV where she is a Partner. LAV originated as the venture arm of Eli Lilly & Co. in Asia in 2008 and is an independent global healthcare investment firm that focuses on various stages of investment opportunities from start-up to commercialization in the life science and healthcare sectors. Dr. Lu previously served as a Managing Director at Orbimed Advisors, LLC in Asia.

“I have been impressed by Avedro’s progress with the adoption of its corneal remodeling products and at the pace by which market access is expanding in the U.S.,” said Dr. Lu, “I am privileged to be given an opportunity to work with a group of experienced industry veterans and investors to help Avedro further advance its clinical programs and discover new, non-invasive ways to improve vision for patients around the world.”

About Lilly Asia Ventures (LAV)

Lilly Asia Ventures (LAV), founded in 2008 and headquartered in Shanghai with offices in the Bay Area and Hong Kong, is a life sciences and healthcare sector focused investment firm, focusing predominantly on biopharmaceutical, med tech and diagnostics investments. As a leading life science investment fund, LAV provides capital, industry expertise, and global resources to its portfolio companies to accelerate their growth.

About Avedro, Inc.

Avedro is a privately held pharmaceutical and medical device company and the world leader in corneal remodeling. Our patented cross-linking technology, consisting of drug formulations and medical devices, are approved for sale in numerous countries around the globe. We continue to develop proprietary corneal remodeling products for the treatment of keratoconus, corneal ectasia and for refractive correction as an alternative to contacts and eyeglasses. Keratoconus and corneal ectasia are rare and sight-threatening eye conditions in which the cornea progressively thins and weakens causing the development of a cone-like bulge and optical irregularity of the cornea which can result in significant visual impairment.

At Avedro, our mission is to produce and deliver innovative, minimally invasive drugs and devices for corneal remodeling to eye care professionals around the world to improve patients’ vision and quality of life.

Avedro Contact

David Iannetta

Avedro, Inc.

Telephone: [phone]

[e-mail]

Media Contact

Michele Gray

Gray Communications, LLC.

Telephone: [phone]

[e-mail]

近期文章

Portfolio公司新闻

行业趋势

原创

欢迎关注：